Table 1 Baseline characteristics of the discovery and validation cohorts of LB patients and controls
Characteristic | Discovery | Validation | ||
|---|---|---|---|---|
LB patients (n = 506) | Controls (n = 313) | LB patients (n = 557) | Controls (n = 441) | |
Male sex—no (%) | 197 (38.9%) | 141 (43.3%) | 241 (43.3%) | 211 (43.1%) |
Age (years) | ||||
 median [min, max] | 54 [19, 82] | 23 [18, 71] | 56 [19, 87] | 23 [18, 75] |
 mean (SD) | 53.1 (13.3) | 25.9 (10.6) | 53.9 (11.8) | 28.1 (13.5) |
LB manifestation | ||||
 EM | 465 (91.9%) | NA | 556 (99.8%) | NA |
 Disseminated LB | 41 (8.1%) | 1 (0.2%) | ||
 ACA | 18 | 1 | ||
 LNB | 10 | NA | ||
Lyme arthritis | 12 | NA | ||
Othera | 1 | NA | ||